Title
Category
Credits
Event date
Cost
An Interactive Case-Based Review of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates
  • Chronic Lymphocytic Leukemia
  • 2.00 AAPA Category 1 CME credit
  • 2.00 ACPE contact hours
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC contact hours
  • 2.00 Participation
$0.00
The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
Refining Therapeutic Approaches in Relapsed/Refractory Multiple Myeloma: Expert Guidance on Bispecific Antibody Therapy Optimization
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ABIM Medical Knowledge
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Expert faculty provide a comprehensive overview of bispecific antibodies in relapsed/refractory multiple myeloma, including clinical considerations, common toxicities, and prophylaxis and management strategies.
Recorded Presentation from Optimizing Patient Outcomes - Metastatic Castration-Resistant Prostate Cancer: Systemic Therapy Updates
  • Prostate Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
It is important to stay up to date with the latest therapy options available, review the latest mCRPC systemic therapy recommendations, and understand the data behind them.
Unraveling Cancer Pain Dynamics (Recorded Presentations)
$0.00
The goal of this initiative is to provide education to clinicians, involved in the assessment and management of cancer pain in adult patients, on the appropriate and safe use of opioid analgesics, optimizing non-opioid analgesics and adjuvant medications, and integrating non-pharmacological approaches into cancer pain management. Provided by the National Comprehensive Cancer Network in collaboration with The France Foundation.
Archived NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.
Recorded Presentation from Optimizing Patient Outcomes - Targeted Therapies for Thyroid Carcinoma
  • Thyroid Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Thyroid carcinoma is a rare disease; however, it is the seventh most common cancer diagnosed in those assigned female at birth. Greater attention to rare diseases is needed to improve treatment options in general, and specifically for anaplastic thyroid carcinoma.  Pharmacists can play a role in appropriate treatment selection, monitoring, and modification.
NCCN Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology
$0.00
Elevate your oncology practice with expert-led education. Join us to learn how collaboration among oncology professionals can drive better patient outcomes.
Archived NCCN Tumor Boards: New Approaches to the Management of Resectable Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
In recent years, several new systemic therapy regimens were approved by the FDA as additional neoadjuvant or adjuvant treatment options for eligible patients with resectable NSCLC and included in the NCCN Guidelines for NSCLC. Clinicians need to be aware of the updated treatment recommendations to ensure optimal outcomes for patients with early-stage NSCLC.
Archived NCCN Tumor Boards: Treatment Options and Navigating Sequencing of Therapies in Relapsed/Refractory Multiple Myeloma
  • Multiple Myeloma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
With the introduction of many new therapies, the management of multiple myeloma is rapidly changing. A uniform treatment approach cannot be applied to all patients.
NCCN Guidelines® Insights - Survivorship, Version 2.2025
  • Survivorship
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
These NCCN Guidelines Insights summarize the panel’s current recommendations and recent updates regarding physical activity, nutrition, and weight management for cancer survivors.

Pages